Groupama Asset Managment Grows Holdings in Stryker Co. (NYSE:SYK)

Groupama Asset Managment lifted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 51.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,007 shares of the medical technology company's stock after purchasing an additional 681 shares during the quarter. Groupama Asset Managment's holdings in Stryker were worth $727,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in SYK. Trexquant Investment LP bought a new stake in Stryker in the 4th quarter worth $14,836,000. Lokken Investment Group LLC grew its stake in shares of Stryker by 2.2% in the 4th quarter. Lokken Investment Group LLC now owns 3,796 shares of the medical technology company's stock worth $1,367,000 after buying an additional 83 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after acquiring an additional 168,436 shares in the last quarter. Tradewinds LLC. purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $241,000. Finally, National Bank of Canada FI increased its holdings in shares of Stryker by 69.6% in the 4th quarter. National Bank of Canada FI now owns 431,259 shares of the medical technology company's stock worth $155,277,000 after purchasing an additional 177,033 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Down 0.5 %

Shares of NYSE:SYK traded down $1.76 during trading on Monday, hitting $344.04. 1,849,336 shares of the company's stock traded hands, compared to its average volume of 1,323,500. The company has a market cap of $131.32 billion, a price-to-earnings ratio of 44.17, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a 50-day moving average price of $381.69 and a 200-day moving average price of $374.39. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. As a group, research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.98%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. Stifel Nicolaus boosted their target price on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Barclays raised their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group boosted their price objective on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.